OXTHERA
OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria.
OXTHERA
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2005-01-01
Address:
Stockholm, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.oxthera.com
Total Employee:
11+
Status:
Active
Contact:
(468) 660-0223
Email Addresses:
[email protected]
Total Funding:
87.56 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Domain Not Resolving
Similar Organizations
Lucira Health
Lucira Health is a biotechnology company that offers disposable test kits to detect RNA and DNA of infectious diseases.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
Molecular Health
Molecular Health offers software solutions for evidence-based healthcare decision support and smarter drug development.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Tandem Diabetes Care
Tandem diabetes care provides products that empower both people with diabetes and those who care for them.
Current Advisors List
Current Employees Featured
Founder
Investors List
Life Sciences Partners
Life Sciences Partners investment in Series D - OxThera
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Series D - OxThera
Idinvest Partners
Idinvest Partners investment in Series D - OxThera
Brohuvudet
Brohuvudet investment in Series D - OxThera
Kurma Partners
Kurma Partners investment in Series D - OxThera
Ysios Capital
Ysios Capital investment in Series D - OxThera
Industrifonden
Industrifonden investment in Series D - OxThera
Flerie Invest
Flerie Invest investment in Series D - OxThera
Kurma Partners
Kurma Partners investment in Venture Round - OxThera
Idinvest Partners
Idinvest Partners investment in Venture Round - OxThera
Official Site Inspections
http://www.oxthera.com Semrush global rank: 5.76 M Semrush visits lastest month: 1.45 K
- Host name: rackfish-websrv03.ad.rackfish.net
- IP address: 194.169.225.47
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "OxThera"
About Us - OxThera
OxThera AB was founded in 2005 to explore the therapeutic potential that originated from this observation. Turning a naturally occurring bacteria into a healthcare product may sound easy, but in reality, it is not. To commercialize …See details»
OxThera - Crunchbase Company Profile & Funding
OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s …See details»
Owners - OxThera
Trademarks: The following trademarks are owned and protected by OxThera and should not be …See details»
OxThera Company Profile 2024: Valuation, Funding
OxThera General Information Description. Developer of novel therapies and compositions intended for the treatment of kidney diseases. The company …See details»
OxThera Company Profile - Office Locations, Competitors ... - Craft
OxThera has 5 employees across 2 locations, $53.3 m in total funding, and kr11.01 m in …See details»
OxThera - eqtgroup.com
Nov 22, 2024 oxthera.com. Latest news. 26 November 2024 EQT portfolio company Parcel2Go announces new ownership; 22 November 2024 EQT Exeter To Acquire More Than One Million Square Feet of Class A Bulk Distribution …See details»
OxThera - Funding, Financials, Valuation & Investors - Crunchbase
OxThera develops products for the treatment of metabolic disorders resulting from excess …See details»
Organizational update - New board member and new CFO
Jun 1, 2020 OxThera AB is a Swedish biotech company developing a new treatment for …See details»
OxThera - VentureRadar
OxThera is a spin-out company from Q-Med AB. OxThera develops products using its cell- and …See details»
Contact Us - OxThera
Trademarks: The following trademarks are owned and protected by OxThera and should not be …See details»
OxThera - Contacts, Employees, Board Members, Advisors & Alumni
OxThera develops products for the treatment of metabolic disorders resulting from excess …See details»
OxThera - Sunstone
OxThera. OxThera AB (Stockholm, Sweden) is a biopharmaceutical company developing an …See details»
OxThera Receives Rare Pediatric Disease Designation from U.S.
Jun 29, 2020 OxThera AB is a Swedish biopharmaceutical company developing a new …See details»
OxThera reports results from Phase 3 ePHex study with Oxabact in ...
Jun 11, 2021 OxThera's 52-week OC5-DB-02 study "A Phase III Double-Blind, Randomised …See details»
Oxthera is Set to Cure a Hyperoxaluria, a Rare Kidney Disease
Jun 16, 2017 Mission: Stockholm-based Oxthera is currently advancing two late-stage clinical …See details»
OxThera reports results from Phase 3 ePHex study with Oxabact in ...
STOCKHOLM, June 11, 2021 /PRNewswire/ -- OxThera AB, a privately-held …See details»
Press Releases - OxThera
Organizational update - New board member and new CFO 2020-06-01. Kirsti Gjellan is new …See details»
OxThera reports results from Phase 3 ePHex study with Oxabact in ...
Jun 11, 2021 OxThera’s 52-week OC5-DB-02 study “A Phase III Double-Blind, Randomised …See details»
Pipeline - OxThera
To address PH, OxThera has taken a bacterial strain isolated from the human gut and …See details»